Credit: Vall d’Hebron Institute of Oncology (VHIO).
- Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study* show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.
- 80% of patients included in this study presented with FolRα expression levels higher than 25%. The overall response rate among these patients was 43.8% in the dose expansion cohort, with a median duration of response of 5.5 months.
- These results support further clinical study of this novel ADC in these patients with advanced ovarian cancer and disease recurrence as a result of platinum chemotherapy resistance.
Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today* by Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.
This global study was designed to evaluate the efficacy and safety of the novel FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin (STRO-002 – luvelta) in patients with recurrent epithelial ovarian cancer with identified expression levels of folate receptor alpha (FolRα) higher than 25%. This ADC induces cytotoxic and immunologic cell death, and using site-specific conjugation technology and is designed to target a broad range of FolRα-expressing ovarian tumors.
“Folate receptor alpha is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies. Its overexpression in solid tumors promotes cancer cell proliferation and persists in metastatic or recurrent disease after therapy. This driver of cancer cell proliferation therefore represents a highly relevant target for the development of novel treatment strategies in ovarian and endometrial cancers,” said Ana Oaknin, Medical Oncologist at the Vall d’Hebron University Hospital (HUVH), and first author of this present study.
STRO-002-GM1 enrolled 44 patients with advanced ovarian cancer and disease recurrence as a result of platinum chemotherapy resistance after 1-3 prior lines of treatment or platinum sensitive disease after 2-3 previous lines of platinum chemotherapy. FolRα expression was not required for study entry but was analyzed retrospectively in archival tissue to evaluate if the overexpression of this protein could potentially guide patient selection.
Patients were randomized 1:1 to receive luveltamab at 4.3 mg/kg or 5.2 mg/kg (23 patients and 21 patients, respectively). 33 of the 44 patients enrolled in this study presented with FolRα expression levels higher than 25%. The dose expansion data show significant clinical benefit in those patients selected for presenting FolRα expression >25%, with an overall response rate of 37.5%. The investigators observed a 44% response rate in those patients who received treatment with the higher 5.2 mg/kg dose.
The most common adverse events included neutropenia, arthralgia and anemia that were managed with standard medical treatment and dose reductions. Neutropenia had a higher incidence at 5.2 mg/kg than 4.3 mg/kg. While treatment adverse events led to dose reduction in 76% of patients treated with the 5.2 mg/kg dose, treatment was only suspended in one patient.
“These dose expansion data confirm the encouraging activity of luveltamab tazevibulin at starting doses ranging from 4.3 to 5.2 mg/kg in patients with recurrent, platinum resistant ovarian cancer with FolRα expression levels of more than 25%, and support further clinical evaluation. Led by VHIO investigators in Europe, a global phase II/III study is already planned to evaluate this novel ADC in this patient population,” concluded Ana Oaknin.
###
Reference:
*Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. Ana Oaknin, Lorena Fariñas-Madrid, Carmen García-Duran, Lainie Martin, David O’Malley, Russell Schilder, Denise Uyar, John Moroney, John Diaz, Alexander Spira, Jesus Garcia-Donas, Michael Palumbo, Hatem Dokainish, Lin Liu, Craig Berman, R. Naumann.
Abstract #: 5508
Track: Gynecologic Cancer
Type: Oral Abstract Session
Location: Hall D1 | Live Stream
Chairs: Christina Annunziata – Tanja Pejovic
Time: 3 June 2023, 22:00 – 01:00 CEST
—-
About VHIO
The Vall d’Hebron Institute of Oncology (VHIO), established in 2006 and located within the Vall d’Hebron Campus, is a reference center for personalized medicine in oncology. Through our purely translational and multidisciplinary research model, we aim to improve the prevention, early diagnosis and treatment of cancer by transforming the latest scientific discoveries made in the laboratory into early phase clinical trials for the development of more effective therapies to improve the quality of life and survival of cancer patients.
VHIO forms part of the CERCA – Research Centres of Catalonia system and is accredited as a Severo Ochoa Center of Excellence.
Research at VHIO would not be possible without the support received from our patrons – Generalitat de Catalunya, Fundació Privada CELLEX, “La Caixa” Foundation, Fundación FERO, and the Fundación BBVA, the public funding it receives as well as the generous support from institutional supporters, private institutions, companies, associations, societies, and individual donors. Only with such continued support will VHIO continue to advance personalized and targeted therapies against cancer.